Table 3.
Novel agents in trials for PTCL.
| Agent | Mechanism of action | Stage of development | Agent type/route |
|---|---|---|---|
| Belinostat | HDAC inhibition | Phase II | SMI/IV |
| Dasatinib | ABL, SRC, Ckit, EPHA, PDGFb | Phase I/II | SMI/oral |
| Tipifarnib | Farnesyl transferase inhibition | Phase II | SMI/oral |
| Plitidepsin | Activation of JNK and MAPK | Phase II | Peptide/IV |
| KW-0761 | Anti-CCR4 antibody | Phase II | MoAB/IV |
| Lenalidomide | Immunomodulation | Phase II | SMI/oral |
| Zanolimumab | Anti-CD4 antibody | Phase II | MoAB/IV |
| A-dmDT390-bisFv | Anti-CD3-diftitox | Phase I | ADC/IV |
| Crizotinib | ALK-1 inhibition | Phase I | SMI/oral |
| Forodesine | PNP inhibition | Phase I | NA/oral |
| Alisertib | Aurora kinase inhibition | Phase II/III | SMI/oral |
*
Patients proceeding to autologous or allogeneic SCT after achieving response with single agent therapy.
ADC, antibody drug conjugate; ALK-1, activin receptor-like kinase-1; EPHA, ephrin-A; HDAC, histone deacetylase; IV, intravenous; JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; MoAB, monoclonal antibody; NA, not applicable; PDGFb, platelet-derived growth factor b; PNP, purine nucleoside phosphorylase; PTCL-U, peripheral T-cell lymphoma ; SMI, small molecule inhibitor.